The grilling that pharmaceutical company executives are expected to face Tuesday before the Senate Finance Committee is reminiscent of previous hearings with businesses that proved to be turning points; UnitedHealthcare lost its case to prevent a former executive from working at the new healthcare venture formed by Amazon, Berkshire Hathaway, and JPMorgan Chase; a bill to establish work requirements for thousands of Medicaid recipients in Wyoming passed its first reading in the state’s House.
The grilling that pharmaceutical company executives are expected to face Tuesday before the Senate Finance Committee is reminiscent of previous hearings with businesses that proved to be turning points, leading to massive reforms of Wall Street banks, the health insurance industry, and tobacco companies, Politico said. The 7 executives set to appear are prepping with the counsel of lawyers and communications consultants in order to strike the right balance of contrition while highlighting the life-saving potential of their products.
UnitedHealthcare lost its case to prevent a former executive from working at the new healthcare venture formed by Amazon, Berkshire Hathaway, and JPMorgan Chase, The New York Times reported. David William Smith was an executive at Optum, a unit of UnitedHealth, and the insurer accused him of taking corporate secrets to his new job. Smith has denied any wrongdoing. A federal judge in Boston denied UnitedHealth’s request to have Smith stop working in his new role.
A bill to establish work requirements for thousands of Medicaid recipients in Wyoming passed its first reading on Friday in the state’s House, The Hill reported. The measure would require “able-bodied” Wyoming residents to work 20 hours per week to qualify for Medicaid benefits. The bill now must survive 2 more votes in the House, according to the Star Tribune, before heading to the desk of Republican Governor Mark Gordon, who has previously opposed Medicaid expansion.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More